Table 1.

Clinical features of t‐NEPC cases treated with olaparib

No.	Author	At the diagnosis of prostate adenocarcinoma					Time to NEPC	At the diagnosis of t‐NEPC						Outcome	Survival from NEPC diagnosis
		Age, year	PSA, ng/mL	Gleason score	Tumor stage	Treatment		PSA, ng/mL	NSE, ng/mL	proGRP, pg/mL	Sites of organ metastasis	BRCA mutation	Treatment
1	Turina, et al. 2019 13	N/A	9.23	4 + 4	pT3bN0	Local treatment: RP 1st line: ADT 2nd line: ENZ	73 week	9.93	N/A	N/A	Liver, bladder	BRCA2 Copy number loss	1st line: ETP + CBDCA maintenance therapy: olaparib	NED	51 week
2	Wu et al. 2020 14	63	55.13	4 + 4	cT4N1M1b	1st line: GOS + BCL 2nd line: ABI + BCL	7 month	1.5	212.9	976.2	Liver, lung	BRCA1	1st line: olaparib+RT 2nd line: ETP + CDDP	CD	5 month
3	Pandya et al. 2021 15	65	95	4 + 4	M1b	LPR + ABI	16 month	0.5	824	N/A	Liver	BRCA2 (Ser1882*)	1st line: ETP + CBDCA 2nd line: olaparib 3rd line: pembrolizumab 4th line: platinum‐based chemotherapy	CD	18 month
4	Naiki et al. 2022 16	63	20.3	4 + 3	cT2N1M1a	Surgical castration+ABI	10 month	N/A	27.4	N/A	Liver, bone	BRCA2 (H1223fs*9)	1st line: ETP + CDDP 2nd line: amrubicin 3rd line: olaparib	CD	10 month
5	Miyazawa Y, et al. 2022–2 cases 17	70	40.8	4 + 5	cT3bN1M1b	CAB+RT(prostate)	36 month	<0.01	171	N/A	Liver, bone	BRCA2	1st line: ETP + CDDP 2nd line: ENZ 3rd line: olaparib	AWD	N/A
6		78	15.2	4 + 4	cT3bN0M0	Local treatment: RP 1st line: ADT 2nd line: BCL 3rd line: ENZ 4th line: DTX 5th line: CBZ	N/A	N/A	N/A	N/A	Bladder	BRCA2	1st line: ETP + CBDCA 2nd line: olaparib	AWD	N/A
7	Kaitsumaru M, et al. 2023 18	67	29.99	5 + 5	M1b	1st line: LPR + ENZ 2nd line: DTX	20 month	0.19	211	53.5	Liver, bone	BRCA1 (deletion of intron 3–7)	1st line: olaparib	CD	6 month
8	The present case	64	6.5	4 + 5	cT3N0M0	Local treatment: RP 1st line: ADT 2nd line: salvage RT	132 month	0.001	31.8	65.8	None	BRCA2 (D427fs*3)	1st line: ETP + CBDCA 2nd line: olaparib	AWD	40 month